Floatz logo

Empagliflozin

Hypoglycemic Agents

SINA Health Education and Welfare TrustSmall moleculePhase 4 / ApprovedActive
BBB
75/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
62/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Hypoglycemic Agents cohort.

Asset / SponsorPhaseRating
Humulin R
SINA Health Education and Welfare Trust
Phase 4BB
Metformin
SINA Health Education and Welfare Trust
Phase 4BB
Pioglitazone
Yonsei University
Phase 4BB
Linagliptin
Rabin Medical Center
Phase 3CCC

Same molecule, other indications

Empagliflozin is also rated in:

metabolic dysfunction-associated steatotic liver diseaseDormant
BBB
Indicative ·
76 / 100
View asset →
prediabetes syndromeDormant
BBB
Indicative ·
74 / 100
View asset →
Physiological Effects of DrugsDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →